Sarah Verhoeff

135 Understanding immune checkpoint inhibitors through PET-imaging studies REFERENCES 1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. 2. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. 3. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2019;176(3):677. 4. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. 2017;18(12):e731-e741. 5. de Vries R, Muller M, van der Noort V, et al. Prediction of response to anti-PD-1 therapy in patients with nonsmall-cell lung cancer by electronic nose analysis of exhaled breath. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2019;30(10):1660-1666. 6. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nature Immunology. 2019;20(11):1425-1434. 7. Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res. 2020;10(1):1-11. 8. Verhoeff SR, van den Heuvel MM, van Herpen CML, Piet B, Aarntzen E, Heskamp S. Programmed Cell Death-1/ Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy? PET Clin. 2020;15(1):35-43. 9. Niemeijer A-LN, Oprea-Lager DE, Huisman MC, et al. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer. J Nucl Med. 2021. 10. Bensch F, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852-1858. 11. Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9(1):4664. 12. Vivier D, Sharma SK, Adumeau P, Rodriguez C, Fung K, Zeglis BM. The Impact of FcgammaRI Binding on ImmunoPET. J Nucl Med. 2019;60(8):1174-1182. 13. Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer research. 2013;73(11):3347-3355. 14. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England journal of medicine. 2018;378(2):158-168. 15. Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics. 2016;6(10):1629-1640. 16. Bensch F, Smeenk MM, van Es SC, et al. Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers-The first step towards an imaging warehouse. Theranostics. 2018;8(16):4295-4304. 17. Gorris MAJ, Halilovic A, Rabold K, et al. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. Journal of immunology. 2018;200(1):347354. 7